Perioperative antiviral therapy for patients with hepatitis B virus related hepatocellular carcinoma with low HBV DNA levels
10.3760/cma.j.issn.1007-8118.2017.03.005
- VernacularTitle:低HBV DNA滴度乙型肝炎相关性肝细胞癌围手术期的抗病毒治疗
- Author:
Baohong YUAN
;
Ruhong LI
;
Jianhong ZHONG
;
Bangde XIANG
;
Weiping YUAN
;
Lequn LI
- Keywords:
Hepatitis B;
Hepatocellular carcinoma;
Antiviral therapy;
Perioperative period
- From:
Chinese Journal of Hepatobiliary Surgery
2017;23(3):162-165
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the role of perioperative antiviral therapy with Entecavir for patients with hepatitis B virus related hepatocellular carcinoma (HBV-HCC) with low serum HBV DNA levels.Methods The HVB-HCC patients were randomly divided into 2 groups.Patients in the antiviral group received Entecavir 4 days before hepatic resection while patients in the control group received no antiviral treatment.The serum HBV DNA,liver function,morbidity and length of hospital stay were compared between the two groups.Results Sixteen patients in the control group (n =44) developed HBV reactivation.On the other hand,only 1 patient in the antiviral group (n =44) developed HBV reactivation.Recovery in liver function in the antiviral group was much faster than the control group,especially for glutamic-pyruvic transaminase level.The antiviral group had significantly lower morbidity and shorter total or postoperative hospitalization (all P ＜ 0.05).Conclusions Patients with HBV-HCC with low levels of HBV DNA have a high risk of developing HBV reactivation in the perioperative period.Perioperative antiviral therapy was safe and efficacious in preventing HBV reactivation,improved liver function,reduced postoperative complications and shortened hospitalization.
